After a roller coaster of a year for Duchenne muscular dystrophy (DMD) gene therapy Elevidys (delandistrogene moxeparvovec), Sarepta Therapeutics Inc. looks to focus on the efficacy narrative in 2026, starting with newly unveiled three-year data showing durable efficacy across all key motor function assessments for treated DMD patients vs. external controls.
Biopharma happenings, including deals and partnerships, and other news in brief: Antev, Dilafor, Exeltis, Galderma, Ipsen, Karolinska, Lifearc, Medicus, Resolve M.
It’s official. A year after President Donald Trump issued an order requiring the U.S. to withdraw from the World Health Organization (WHO), that withdrawal has been completed.
RSS
